Rosen Quoted on Interchangeability and Biosimilar Guidances
January 7, 2015
BioWorld Today
Partner David Rosen was quoted in a BioWorld Today article, “FDA: Interchangeability, Other Guidances for Biosimilars in the Works,” on January 7, 2015. The article discussed possible FDA guidance changes on interchangeability, biosimilar draft guidance on labeling, statistical approaches for analyzing similarities in data, and implications of Biologic Price Competition and Innovation Act (BPCIA).
Rosen was quoted saying, “Some of the differences of opinion may be one of the reasons the guidances are a long time in coming. For instance, concerns about the potential market impact of naming and interchangeability guidelines could subject the drafts to the interagency review process.”
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“